Home » Pharma News » Ajanta Pharma launches drug in US and other top pharma news

Ajanta Pharma launches drug in US and other top pharma news

Ajanta Pharma launches drug in US and other top pharma news

The National Pharmaceutical Pricing Authority (NPPA) has slapped show-cause notices on 10 top drugmakers, including Sun Pharma, Lupin and Aurobindo Pharma, for not submitting relevant information about the names of formulations manufactured and marketed by them. Besides these companies, notices have also been sent to a few other smaller firms.

Doctor prescription and medicine
Ajanta Pharma on Tuesday announced the launch of the anti-dementia Memantine Hydrochloride tablets in the US market. It is a bio-equivalent to generic version of Namenda. (FC)

The National Pharmaceutical Pricing Authority (NPPA) has slapped show-cause notices on 10 top drugmakers, including Sun Pharma, Lupin and Aurobindo Pharma, for not submitting relevant information about the names of formulations manufactured and marketed by them. Besides these companies, notices have also been sent to a few other smaller firms. (HT)

Drug firm Suven Life Sciences has received a patent each from Canada and Hong Kong for molecules to be developed as drugs for treatment of various central nervous system disorders. The product patents are “valid through 2032 and 2030, respectively,” Suven Life Sciences said in a filing to BSE. With these new patents, the company has a total of 23 patents from Canada and 20 patents from Hong Kong, it added. The new chemical entities (NCEs) are being developed for the treatment of cognitive impairment associated with neuro-degenerative disorders such as Alzheimer’s disease, Parkinson and Schizophrenia, Suven Life Sciences said. (HBL)

Indian drugmakers are embarking on a research spending spree to master more complex therapies and their billionaire founders look willing to absorb the costs. The goal? To reach more people like Ryan Matzner, an asthma patient who lives thousands of miles away in New York. For years, the 31- year-old app developer has been a regular buyer of a pocket-sized purple disc made by GlaxoSmithKline Plc that helps keep his airways from clogging. (FC)

Proton Pump Inhibitors (PPIs), commonly known as the ‘Purple Pill’, which people pop routinely to get rid of their heartburn, could, if taken over long term, lead to some serious health risks. In the US and some countries, these wonder drugs are available as OTC (over the counter) drugs for treating gastric acid reflux diseases (GERD). These drugs are also prescribed for long-term use in our country. The US Food and Drug Administration (USFDA) recommended use of these drugs for 4-8 weeks only. Now, fresh evidence is emerging that their overuse could lead to trouble for the heart, kidney and brain. Flagging this lurking danger signal is June 10 paper published in the Circulation Research, an American Heart Association Journal. (HBL)

Ziarco Pharma, a UK biotechnology company whose investors include Pfizer’s venture capital arm, is exploring a sale after it got positive study results for a dermatology treatment, according to people with knowledge of the matter. The sale could fetch more than $1 billion. (FE)

Thanks for the comment

BIGTheme.net • Free Website Templates - Downlaod Full Themes
Social Media Auto Publish Powered By : XYZScripts.com